| Literature DB >> 25861257 |
Lin Li1, Lingling Li2, Xiaoying Zhou1, Shuping Xiao1, Huiyuan Gu1, Guoxin Zhang1.
Abstract
Background. Several studies have shown a possible involvement of Helicobacter pylori (H. pylori) infection in individuals with hyperemesis gravidarum (HG), but the relationship remains controversial. This meta-analysis was performed to validate and strengthen the association between HG and H. pylori infection. Methods. PubMed, Embase, and Web of Science databases up to March 20, 2014, were searched to select studies on the prevalence of H. pylori infection between pregnant women with HG and the normal pregnant control subjects. Results. Of the HG cases, 1289 (69.6%) were H. pylori-positive; however, 1045 (46.2%) were H. pylori-positive in control group. Compared to the non-HG normal pregnant controls, infection rate of H. pylori was significantly higher in pregnant women with HG (OR = 3.34, 95% CI: 2.32-4.81, P < 0.001). Subgroup analysis indicated that H. pylori infection was a risk factor of HG in Asia, Africa, and Oceania, especially in Africa (OR = 12.38, 95% CI: 7.12-21.54, P < 0.001). Conclusions. H. pylori should be considered one of the risk factors of HG, especially in the developing countries. H. pylori eradication could be considered to relieve the symptoms of HG in some intractable cases.Entities:
Year: 2015 PMID: 25861257 PMCID: PMC4378596 DOI: 10.1155/2015/278905
Source DB: PubMed Journal: Gastroenterol Res Pract ISSN: 1687-6121 Impact factor: 2.260
Figure 1Flow chart of the literature searches for evaluating Helicobacter pylori infection and hyperemesis gravidarum.
Characteristics of studies on H. pylori infection in HG cases and controls.
| First author, year | Study design | Country | Sample size | HG definition | Detection method | Gestational age when included in the study | Sources of pregnant women |
|---|---|---|---|---|---|---|---|
| Frigo, 1998 [ | Case-control | Austria | 234 | Vomiting >3 times/day | Serum IgG antibodies by FEI | — | — |
|
| |||||||
| Perez-Perez, 1999 [ | Case-control | USA | 89 | Vomiting >3 times/day | Serum cagA by ELISA | — | — |
|
| |||||||
|
Koćak, 1999 [ | Case-control | Turkey | 211 | Vomiting >3 times/day | Serum IgG antibodies by FEI | 7–16 weeks | 141 Primigravida |
|
| |||||||
| Hayakawa, 2000 [ | Case-control | Japan | 63 | Nausea and vomiting in first trimester | Serum IgG antibodies by ELISA | The first trimester | — |
|
| |||||||
|
Sahin, 2000 [ | Case-control | Turkey | 120 | Prolonged severe vomiting | Serum IgG antibodies by ELISA | — | — |
|
| |||||||
| Reymunde, 2001 [ | Case-control | Puerto Rico | 89 | Daily nausea and vomiting in gestation weeks 6–16 | Serum IgG antibodies not specified | 6–16 weeks | — |
|
| |||||||
| Kazerooni, 2002 [ | Case-control | Iran | 107 | Vomiting >3 times/day | Serum IgG antibodies by ELISA | 7–16 weeks | 62 Primigravida |
|
| |||||||
| Bagis, 2002 [ | Case-control | Turkey | 30 | Severe HG in the first 16 weeks of pregnancy | Endoscopy with biopsy + histological examination | 16 weeks | — |
|
| |||||||
| Erdem, 2002 [ | Case-control | Turkey | 86 | Vomiting >4 times/day | Serum IgG antibodies by ELISA | — | — |
|
| |||||||
| Berker, 2003 [ | Case-control | Turkey | 240 | Vomiting >3 times/day | Serum IgG antibodies by ELISA | 10–14 weeks | 55 Primigravida |
|
| |||||||
| Jacobson, 2003 [ | Case-control | Canada | 206 | Vomiting >3 times/day | Serum IgG antibodies by ELISA | 7–19 weeks | — |
|
| |||||||
| Salimi-Khayati, 2003 [ | Case-control | Iran | 108 | Vomiting >3 times/day | Serum IgG antibodies by ELISA | 6–16 weeks | 93 Primigravida |
|
| |||||||
| Karaca, 2004 [ | Case-control | Turkey | 146 | Vomiting >3 times/day | Serum IgG antibodies by FEI | — | — |
|
| |||||||
| Cevrioglu, 2004 [ | Case-control | Turkey | 124 | Vomiting >3 times/day | Serum IgG antibodies by ELISA | The first 16 weeks | — |
|
| |||||||
| Xia, 2004 [ | Case-control | China | 172 | Vomiting >3 times/day | Serum specific IgG antibodies and CagA by ELISA | 7–16 weeks | 172 Multigravida |
|
| |||||||
| Jamal, 2004 [ | Case-control | Iran | 94 | Vomiting >3 times/day | Serum IgG antibodies by ELISA | 7–16 weeks | 49 Primigravida |
|
| |||||||
| Lee, 2005 [ | Cross-sectional | USA | 82 | Vomiting >3 times/day | Serum IgG antibodies by ELISA | — | — |
|
| |||||||
| Karadeniz, 2006 [ | Case-control | Turkey | 60 | Vomiting >3 times/day | Serum IgG antibodies by ELISA | 8–14 weeks | — |
|
| |||||||
| Özcimen, 2006 [ | Cross-sectional | Turkey | 140 | Vomiting >3 times/day | Serum IgG antibodies by ELISA | — | — |
|
| |||||||
| Tuncel, 2006 [ | Case-control | Turkey | 138 | Vomiting >3 times/day | Serum IgG antibodies by ELISA | — | — |
|
| |||||||
| Hatziveis, 2007 [ | Case-control | Greece | 110 | Vomiting >3 times/day | Serum IgG antibodies by ELISA | 8–14 weeks | 39 Primigravida |
|
| |||||||
| Güney, 2007 [ | Case-control | Turkey | 60 | Vomiting >4 times/day | Serum IgG antibodies not specified | 7–12 weeks | — |
|
| |||||||
| Aytac, 2007 [ | Case-control | Turkey | 107 | Vomiting >3 times/day | Stool antigen by ELISA | 8–13 weeks | — |
|
| |||||||
| Sandven, 2008 [ | Case-control | Norway | 488 | ICD-9 Code 643.1 | Serum IgG antibodies by EIA | ||
|
| |||||||
| Mansour, 2009 [ | Case-control | Egypt | 100 | Vomiting >3 times/day | Serum IgG antibodies by ELISA | 10–16 weeks | 67 Primigravida |
|
| |||||||
| Guven, 2011 [ | Cross-sectional | Turkey | 80 | Vomiting >3 times/day | Serum IgG antibodies by ELISA | 7–12 weeks | — |
|
| |||||||
| Mansour, 2011 [ | Case-control | Egypt | 160 | Vomiting >3 times/day | Serum IgG antibodies by ELISA | 10–16 weeks | — |
|
| |||||||
| Bezircioğlu, 2011 [ | Case-control | Turkey | 72 | Vomiting >4 times/day | Stool antigen by ELISA | 10–14 weeks | — |
|
| |||||||
| Epstein, 2012 [ | Case-control | USA | 82 | Met the diagnosis of hyperemesis | Serum IgG antibodies by ELISA | — | — |
|
| |||||||
| Vikanes, 2013 [ | Case-control | Norway | 170 | Long-lasting nausea and vomiting, weight loss, | Serum IgG antibodies and CagA and VacA by EIA | 17th and 22nd | — |
|
| |||||||
| Güngören, 2013 [ | Case-control | Turkey | 140 | Vomiting 3 times/day | Serum IgG antibodies by ELISA | Below the 20th week | — |
|
| |||||||
| Shaban, 2014 [ | Case-control | Egypt | 100 | Vomiting >3 times/day | Serum IgG antibodies by membrane-based immunoassay | 5–12 weeks | 36 Primigravida |
HP: Helicobacter pylori; HG: hyperemesis gravidarum; FEI: fluorescent enzyme immunoassay; EIA: enzyme immunoassay; ELISA: enzyme-linked immunosorbent assay.
Statistical analysis of studies on the rate of H. pylori infection in HG cases and non-HG controls.
| First author, year | Number of cases | Number of controls | Number of cases with HP (+), | Number of controls with HP (+), | OR (95% CI) |
|---|---|---|---|---|---|
| Frigo, 1998 [ | 105 | 129 | 95 (90.5) | 60 (46.5) | 10.93 (5.22, 22.85) |
| Perez-Perez, 1999 [ | 42 | 47 | 8 (19.1) | 12 (25.5) | 0.69 (0.25, 1.89) |
|
Koćak, 1999 [ | 95 | 116 | 87 (91.5) | 52 (44.8) | 13.38 (5.95, 30.13) |
| Hayakawa, 2000 [ | 34 | 29 | 18 (52.9) | 6 (20.6) | 4.31 (1.40, 13.25) |
|
Sahin, 2000 [ | 60 | 60 | 37 (61.7) | 32 (53.3) | 1.41 (0.68, 2.91) |
| Reymunde, 2001 [ | 45 | 44 | 40 (89.0) | 3 (7.0) | 109.33 (24.49, 488.12) |
| Kazerooni, 2002 [ | 54 | 53 | 44 (81.5) | 29 (54.7) | 3.64 (1.52, 8.73) |
| Bagis, 2002 [ | 20 | 10 | 19 (95.0) | 5 (50.0) | 19.00 (1.79, 201.68) |
| Erdem, 2002 [ | 47 | 39 | 40 (85.1) | 25 (64.1) | 3.20 (1.14, 9.02) |
| Berker, 2003 [ | 80 | 80 | 56 (70.0) | 49 (61.2) | 1.48 (0.77, 2.85) |
| Jacobson, 2003 [ | 53 | 153 | 19 (35.7) | 45 (29.7) | 1.34 (0.69, 2.60) |
|
Salimi-Khayati, 2003 [ | 54 | 54 | 48 (88.9) | 22 (40.7) | 11.64 (4.25, 31.87) |
| Karaca, 2004 [ | 56 | 90 | 46 (82.1) | 58 (64.4) | 2.54 (1.13, 5.70) |
| Cevrioglu, 2004 [ | 27 | 97 | 23 (85.2) | 71 (73.2) | 2.11 (0.66, 6.67) |
| Xia, 2004 [ | 72 | 100 | 64 (88.9) | 45 (45.0) | 9.78 (4.25, 22.51) |
| Jamal, 2004 [ | 39 | 55 | 26 (66.7) | 23 (41.8) | 2.78 (1.18, 6.54) |
| Lee, 2005 [ | 40 | 42 | 26 (65.0) | 28 (66.7) | 0.93 (0.37, 2.31) |
| Karadeniz, 2006 [ | 31 | 29 | 21 (67.7) | 23 (79.3) | 0.55 (0.17, 1.77) |
| Özcimen, 2006 [ | 70 | 70 | 35 (50.0) | 33 (47.1) | 1.12 (0.58, 2.18) |
| Tuncel, 2006 [ | 50 | 88 | 48 (96.0) | 73 (82.9) | 4.93 (1.08, 22.54) |
| Hatziveis, 2007 [ | 25 | 85 | 14 (56.0) | 41 (48.2) | 1.37 (0.56, 3.35) |
| Güney, 2007 [ | 25 | 20 | 20 (80.0) | 10 (50.0) | 4.00 (1.07, 14.90) |
| Aytac, 2007 [ | 52 | 55 | 22 (42.3) | 22 (40.0) | 1.10 (0.51, 2.38) |
| Sandven, 2008 [ | 244 | 244 | 105 (43.0) | 58 (23.8) | 2.42 (1.64, 3.57) |
| Mansour, 2009 [ | 50 | 50 | 42 (84.0) | 18 (36.0) | 9.33 (3.60, 24.17) |
| Guven, 2011 [ | 40 | 40 | 32 (80.0) | 14 (35.0) | 7.43 (2.70, 20.42) |
| Mansour, 2011 [ | 80 | 80 | 71 (88.8) | 24 (30.0) | 18.41 (7.93, 42.74) |
| Bezircioğlu, 2011 [ | 36 | 36 | 8 (22.2) | 1 (2.8) | 10.00 (1.18, 84.78) |
| Epstein, 2012 [ | 23 | 59 | 16 (69.6) | 38 (64.4) | 1.26 (0.45, 3.56) |
| Vikanes, 2013 [ | 62 | 108 | 38 (61.3) | 67 (62.0) | 0.97 (0.51, 1.84) |
|
Güngören, 2013 [ | 90 | 50 | 75 (83.3) | 30 (60.0) | 3.33 (1.51, 7.36) |
| Shaban, 2014 [ | 50 | 50 | 46 (92.0) | 28 (56.0) | 9.04 (2.82, 28.95) |
HG: hyperemesis gravidarum; OR: odds ratio; CI: confidence interval.
Figure 2Meta-analysis for the association between HG and Helicobacter pylori infection.
Subgroup analysis of the prevalence of H. pylori infection in HG cases versus controls.
| Subgroup | Number of studies | Cases with HP (+) | Controls with HP (+) | OR [95% CI] |
|
| Tests of heterogeneity | |||
|---|---|---|---|---|---|---|---|---|---|---|
|
| df |
|
| |||||||
| Region | ||||||||||
| Asia | 20 | 769/1017 | 593/1121 | 3.27 [2.18, 4.91] | <0.001 | 5.71 | 68.04 | 19 | <0.001 | 72.1 |
| North America | 5 | 109/203 | 28/345 | 2.33 [0.63, 8.62] | 0.205 | 1.27 | 36.55 | 4 | <0.001 | 89.1 |
| Europe | 3 | 157/331 | 166/437 | 1.55 [0.83, 2.91] | 0.170 | 1.37 | 6.18 | 2 | 0.046 | 67.6 |
| Africa | 3 | 159/180 | 70/180 | 12.38 [7.12, 21.54] | <0.001 | 8.91 | 1.47 | 2 | 0.479 | 0 |
| Oceania | 1 | 95/105 | 60/129 | 3.34 [2.32, 4.81] | <0.001 | 6.35 | 0.00 | 0 | — | — |
| Year | ||||||||||
| 1996–2000 | 5 | 245/336 | 162/381 | 3.66 [1.17, 11.48] | 0.026 | 2.23 | 35.41 | 4 | <0.001 | 88.7 |
| 2001–2005 | 12 | 451/587 | 403/817 | 3.89 [2.10, 7.21] | <0.001 | 4.32 | 57.01 | 11 | <0.001 | 80.7 |
| 2006–2010 | 8 | 307/547 | 278/641 | 2.01 [1.15, 3.49] | 0.014 | 2.47 | 24.07 | 7 | 0.001 | 70.9 |
| 2011–2014 | 7 | 286/381 | 202/423 | 4.41 [1.72, 11.29] | 0.002 | 3.09 | 39.71 | 6 | <0.001 | 84.9 |
| HP testing method | ||||||||||
| HpIgGAb | 29 | 1240/1743 | 1017/2161 | 3.32 [2.28, 4.84] | <0.001 | 6.25 | 158.05 | 28 | <0.001 | 82.3 |
| HpSA | 7 | 124/300 | 124/435 | 1.88 [1.33, 2.65] | 0.0004 | 3.57 | 9.50 | 6 | 0.091 | 47.4 |
| HpDNA PCR | 2 | 45/124 | 10/79 | 5.87 [2.47, 13.93] | <0.001 | 4.02 | 0.63 | 1 | 0.43 | 0 |
| HpIgAAb | 1 | 13/27 | 40/97 | 1.32 [0.56, 3.12] | 0.52 | 0.64 | 0.00 | 0 | — | — |
| HpIgMAb | 1 | 6/90 | 0/50 | 7.77 [0.43, 140.84] | 0.17 | 1.39 | 0.00 | 0 | — | — |
| histologically | 1 | 19/20 | 5/10 | 19.00 [1.79, 201.68] | 0.01 | 2.44 | 0.00 | 0 | — | — |
| All studies | 32 | 1289/1851 | 1045/1217 | 3.34 [2.32, 4.81] | <0.001 | 6.51 | 167.81 | 31 | <0.001 | 81.5 |
HP: Helicobacter pylori; HG: hyperemesis gravidarum; OR: odds ratio; CI: confidence interval; df: degrees of freedom; HpIgGAb: H. pylori IgG antibodies; HpIgAAb: H. pylori IgA antibodies; HpIgMAb: H. pylori IgM antibodies; HpSA: H. pylori stool antigen; Hp DNA PCR: H. pylori genome by PCR.
Figure 3Publication bias tests for the overall data (H. pylori-positive versus H. pylori-negative).
The infection rate of CagA- or VacA-positive H. pylori in HG cases and controls.
| First author, year | Region | Number of cases | Number of controls | Number of cases with CagA- and/or VacA-positive | Number of controls with CagA- and/or VacA-positive | OR (95% CI) |
|---|---|---|---|---|---|---|
| Xia, 2004 [ | Asia | 72 | 100 | 50 (69.4%) | 14 (14%) | 13.96 (6.56, 29.71) |
| Vikanes, 2013 [ | Europe | 62 | 108 | 21 (33.9%) | 44 (40.8) | 0.75 (0.39, 1.43) |
CagA: cytotoxin-associated gene A product; VacA: vacuolating cytotoxin A; HG: hyperemesis gravidarum; OR: odds ratio; CI: confidence interval.